Piper Sandler analyst Allison Bratzel has raised the price target for Replimune Group (REPL, Financial) from $14.00 to $22.00. This adjustment marks a significant 57.14% increase in the price target, reflecting an optimistic outlook for the company's future performance.
The current analyst rating for Replimune Group (REPL, Financial) remains at "Overweight," consistent with the previous rating. This suggests that the analyst believes the stock will outperform its peers in the foreseeable future.
Replimune Group (REPL, Financial) is listed on the NASDAQ exchange and continues to capture the attention of investors and analysts alike with its promising developments in the biotech sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Replimune Group Inc (REPL, Financial) is $22.71 with a high estimate of $31.00 and a low estimate of $17.00. The average target implies an upside of 137.97% from the current price of $9.55. More detailed estimate data can be found on the Replimune Group Inc (REPL) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Replimune Group Inc's (REPL, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
